Evidence map›Paper›PMID 35872627›Full record

ArticleBalkan medical journal2022

FLOT2 Promotes the Proliferation and Epithelial-mesenchymal Transition of Cervical Cancer by Activating the MEK/ERK1/2 Pathway.

Yang Li, Shulan Dou

Open access · diamondAbstract read
In one paragraph

Article in Balkan medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yang LiDepartment of Gynecology, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, China.ORCID 0000-0001-8529-4076
Shulan DouDepartment of Gynecology, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, China.ORCID 0000-0001-6006-2770
Nanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: As prevalent cancer in women, approximately 569,847 cases of cervical cancer occur every year. Aims: This study aimed to explore the role of FLOT2 and its related mechanism in the development of cervical cancer. Study Design: Cell culture study and animal experimentation. Methods: Quantitative reverse-transcription polymerase chain reaction PCR and Western blot analysis were performed to evaluate the expression of FLOT2. Flow cytometry was applied for the evaluation of cell apoptosis. Cell Counting Kit-8 and colony formation were utilized for proliferation measurement. Cervical cancer mice model was employed to measure the role of FLOT2 in vivo. Results: FLOT2 mRNA and protein levels were dramatically elevated ( Conclusion: FLOT2 aggravates the proliferation and epithelialmesenchymal transition of cervical cancer by activating the MEK/ ERK1/2 and AKT pathways.

Indexed as

Epithelial-Mesenchymal TransitionUterine Cervical NeoplasmsAnimalsCadherinsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMAP Kinase Signaling SystemMiceMitogen-Activated Protein Kinase KinasesProto-Oncogene Proteins c-aktVimentinCadherinsMitogen-Activated Protein Kinase KinasesProto-Oncogene Proteins c-aktVimentin

Identifiers

PMID35872627
PMCPMC9326943
OpenAlexW4286698485

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.